The mechanism of action of lithium as a drug for patients with affecti
ve disorders was investigated. Three-week-old male rats were orally ad
ministered 2.7 mEq Li2CO3/kg/d for 1 or 3 wk, and phosphatidylinositol
(PI), phosphatidylinositol 4-phosphate (PIP), phosphatidylinositol 4,
5-bisphosphate (PIP2), inositol phosphate (IP), inositol diphosphate (
IP2) and inositol triphosphate (IP3) levels in brain were measured. Th
e levels of IP were increased 1.7 and 2.4 times after 1 wk and 3 wk of
lithium administration, respectively, while PI, PIP, PIP2, IP2 and IP
3 levels were not altered. IP3 was further fractionated by high-perfor
mance liquid chromatography into I-1,3,4-P3 and I-1,4,5-P3. In the con
trol rat brain, the relative percentages of I-1,3,4-P3 and I-1,4,5-P3
were 95.8 and 4.2, respectively. However, after 3 wk of lithium admini
stration, the values were changed to 69.6 and 30.3%, respectively. Thi
s increase in the neurotransducer I-1,4,5-P3 in the brain may be relev
ant to the mechanism of action in the lithium treatment of patients wi
th manic-depressive disorders.